[Discussion] ATTAIN is doing more work than we give it credit for
Something I keep coming back to: ATTAIN is doing more work than we give it credit for. Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction. Analytically this is a…
Push back: daily dosing is not automatically better adherence. It is a different failure mode, not a solved problem.
Push back: daily dosing is not automatically better adherence.
Adding the standing caveat — unapproved, and research material is not for human use.
nothing containing this is approved anywhere and research material is not for human use
the tolerability profile reads broadly similar to the class
Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.
Careful — purity methods for peptides do not read across to a small molecule and the numbers are not equivalent.
the boards keep comparing it to injectables at matched doses, which is meaningless
Went looking for independent testing on this and found essentially nothing, which was clarifying.
nothing containing this is approved anywhere yet
small molecule, not a peptide, and that changes everything about it
What analytical method was used — this is not the usual peptide assay question?
Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.
a non-peptide agonist does not degrade the way a peptide does